Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume 25, Issue 1, January 2001, Pages 73-89
Alzheimer's disease: current and future therapeutic perspectives
References (90)
- et al.
Mini Mental State: a practical method for grading the cognitive state of patients for the clinician
J. Psychiat. Res.
(1975) - et al.
Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
Lancet
(1998) The five-five, ten-ten plan for Alzheimer's disease
Neurobiol. Aging
(1992)- et al.
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study
Europ. Neuropsychopharmacol.
(1998) Anti-inflammatory therapy for Alzheimer's disease
- et al.
A randomized controlled trial of prednisone in Alzheimer's disease
Neurology
(2000) - et al.
The effects of rivastigmine on behavioral symptoms in severe AD patients in a nuring home setting
Neurobiol Aging
(2000) - et al.
Functional impairment in instrumental activities of daily living: an early clinical sign of dementia?
J.A.G.S.
(1999) - et al.
Survival in Alzheimer's disease and vascular dementia
Neurology
(1985)
Mild Senile Dementia of the Alzheimer Type: 2. Longitudinal Assessment
Ann. Neurol.
(1988)
Factors affecting course and survival in Alzheimer's disease
Arch. Neurol.
(1994)
Donepezil in the treatment of Alzheimer's disease — Results from a multinational clinical trial
Dement. Geriat. Cogn. Disord.
(1999)
A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
Int. J. Geriat. Psychopharmacol.
(1998)
The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease
Neurology
(1998)
Alzheimer's disease. Etiologies, pathophysiology, cognitive reserve, and treatment opportunities
Neurology
(1998)
The dose-related improvement by metrifonate of the cognitive performance of Alzheimer's disease patients
Neurology
(1998)
Predicting conversion to Alzheimer's disease using standardized clinical information
Arch. Neurol.
(2000)
Measurement of quality-of-life changes in patients with Alzheimer's disease
Clin. Ther.
(1989)
Clinical benefits of donepezil: results from a long-term phase III extension trial
Neurology
(1999)
Prospects for pharmacological intervention in Alzheimer's disease
Arch. Neurol.
(2000)
New treatments in Alzheimer Disease and the continued need for placebo-controlled trials
Arch. Neurol.
(1998)
Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
Neurology
(1998)
Metrifonate in the symptomatic treatment of Alzheimer's disease: influence of apolipoprotein E genotype
Neurology
(1998)
Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease
Neurology
(2000)
The Consortium to establish a Registry for Alzheimer's Diseae (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over three years
Neurology
(1995)
Clinical trials and therapy
Current Opinion in Neurology
(1998)
Cholinesterases inhibitors in the treatment of dementia
Effects on decline or deterioration
The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental activities of daily living
Neurology
(1998)
Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment of Dementia
A.J.O.T.
(1999)
Abnormalities of neural circuitry in Alzheimer's disease
Neurology
(1998)
Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy
Estrogen for Alzheimer's disease in women
Neurology
(2000)
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease
Neurology
(1996)
Predictors of time to institutionalization of patients with Alzheimer's disease. The CERAD experience, part XVII
Neurology
(1997)
Predicting who will develop dementia in a cohort of canadian seniors
Can. J. Neurol. Sci.
(2000)
Longitudinal study of cerebrospinal fluid levels of tau, Abeta1-40, and Abeta1-42(43) in Alzheimer's disease: a study in Japan
Ann Neurol.
(1998)
Is the placebo control obsolete in a world after donepezil and vitamin E?
Arch. Neurol.
(1998)
Comparison of annual change of mental status score in four independent studies of patients with Alzheimer's disease
Ann. Neurol.
(1988)
Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open label study
J. Geriatr. Psychiatry Neurol.
(1996)
Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality
Neurology
(1996)
Clinical research designs for emerging treatments to Alzheimer's diseasse: moving beyond placebo-controlled trials
Arch. Neurol.
(1998)
Slowing the progression of Alzheimer's disease: methodological issues
Alz. Dis. Assoc. Disord.
(1997)
Rate of progression and prognostic factors in Alzheimer's disease: a prospective study
J.A.G.S.
(1993)
Cited by (0)
Copyright © 2001 Published by Elsevier Inc.